6 days Ago By Defense World Staff
Corebridge Financial Inc. lessened its stake in KalVista Pharmaceuticals, Inc. ( NASDAQ:KALV – Free Report ) by 17.
9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,945 shares of the specialty pharmaceutical company’s stock after selling 3,682 shares during the period. Corebridge Financial Inc.
’s holdings in KalVista Pharmaceuticals were worth $144,000 at the end of the most recent quarter. Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its holdings in KalVista Pharmaceuticals by 68.
1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc.
acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $634,000. Barclays PLC raised its holdings in shares of KalVista Pharmaceuticals by 418.5% during the third quarter.
Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after acquiring an additional 54,257 shares during the last quarter. SG Americas Securities LLC boosted its stake in KalVista Pharmaceuticals by 10.0% during the 4th quarter.
SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of KalVista Pharmaceuticals by 22.9% during the third quarter.
FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock worth $769,000 after buying an additional 12,397 shares in the last quarter. Wall Street Analyst Weigh In A number of equities analysts recently weighed in on KALV shares. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th.
They set a “buy” rating and a $30.00 price target on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st.
JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price on the stock.
Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company.
Finally, Jones Trading reissued a “buy” rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock.
According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $24.83.
Insider Transactions at KalVista Pharmaceuticals In related news, CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.
82, for a total value of $50,121.28. Following the completion of the transaction, the chief executive officer now directly owns 278,855 shares of the company’s stock, valued at $2,738,356.
10. This represents a 1.80 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available through this hyperlink . Also, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $9.
42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider now owns 5,303,985 shares of the company’s stock, valued at $49,963,538.
70. The trade was a 0.47 % increase in their ownership of the stock.
The disclosure for this purchase can be found here . Over the last ninety days, insiders purchased 261,055 shares of company stock valued at $2,397,646 and sold 17,292 shares valued at $184,625. Corporate insiders own 10.
50% of the company’s stock. KalVista Pharmaceuticals Trading Up 4.0 % NASDAQ:KALV opened at $11.
95 on Tuesday. The firm has a market cap of $594.11 million, a PE ratio of -3.
28 and a beta of 0.39. The stock has a fifty day moving average price of $11.
12 and a 200 day moving average price of $10.30. KalVista Pharmaceuticals, Inc.
has a 12-month low of $7.30 and a 12-month high of $15.50.
KalVista Pharmaceuticals Company Profile ( Free Report ) KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). See Also Five stocks we like better than KalVista Pharmaceuticals CD Calculator: Certificate of Deposit Calculator Why NVIDIA Stock Could Soar Despite Wall Street Downgrades 2 Rising CRM Platform Stocks That Can Surge Higher in 2025 Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold How to Invest in the FAANG Stocks 3 Hot New IPOs Defying the 2025 Market Slump Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
